By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OXiGENE, Inc. 

230 Third Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-547-5900 Fax: 781-547-6800


SEARCH JOBS


Industry
Biotechnology






Company News
OXiGENE (OXGN) Announces Preclinical Poster Presentation On Oxi4503 At Upcoming American Society of Hematology Meeting 11/20/2014 2:17:32 PM
OXiGENE (OXGN) Announces Issuance Of European Patent for OXi4503 In Acute Myeloid Leukemia And Other Myeloid Malignancies 11/17/2014 2:43:50 PM
OXiGENE (OXGN) Reports Third Quarter 2014 Financial Results 11/13/2014 8:08:46 AM
OXiGENE (OXGN) Announces Presentation Of Phase 2 Data Confirming That Addition Of Fosbretabulin To Bevacizumab Significantly Increases Progression-Free Survival In Recurrent Ovarian Cancer 11/10/2014 7:24:44 AM
OXiGENE (OXGN) Announces Third Quarter 2014 Earnings Conference Call And Webcast 10/22/2014 7:32:32 AM
OXiGENE (OXGN) Announces First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin Combined With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer 10/8/2014 7:08:31 AM
OXiGENE (OXGN) Announces Presentation Of Data From The Phase 2 GOG186I Study At The 15th Biennial Meeting Of The International Gynecologic Cancer Society 10/7/2014 7:21:01 AM
OXiGENE (OXGN) Initiates Phase 2 Study Of Fosbretabulin In Gastrointestinal Neuroendocrine Tumors 9/18/2014 7:42:55 AM
OXiGENE (OXGN) Announces Presentation At The Rodman & Renshaw Conference On September 9 8/27/2014 7:57:33 AM
OXiGENE (OXGN) Reports Second Quarter 2014 Financial Results 8/5/2014 3:10:18 PM
12345678910...
//-->